Press Releases

Nov 02, 2022 AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Oct 31, 2022 Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group's Nominations Valid

Oct 26, 2022 AIM ImmunoTech Board Issues Letter to Shareholders

Oct 12, 2022 AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Sep 21, 2022 AIM ImmunoTech to Present at the Virtual Investor Long COVID Event

Sep 19, 2022 AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

Sep 07, 2022 AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 06, 2022 AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

Aug 30, 2022 AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma

Aug 18, 2022 AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer

<< < > >>